A controllable payload layer for targeted oncology.
Boehringer Ingelheim-selected targeting biology can determine where the construct goes. GenLumina adds a light-activated intracellular payload providing an independent spatial control over where cytotoxic activity is activated.
Start with one BI-selected antibody, peptide or ligand and test the combination against predefined criteria.
Designed to be evaluated with different antibodies, peptides and targeting ligands.
Targeted and conjugated in-vitro work across breast and colorectal cancer models.
Molecular targeting controls delivery; light provides a second spatial control layer.
Internal programmes build the evidence; partners can bring targeting biology from their own pipelines.
A potential fit with BI's technology-partnering interests.
Boehringer Ingelheim publicly identifies new modalities beyond small molecules, targeted intracellular delivery technologies and biologic enabling technologies among its partnering interests. GenLumina's controllable payload architecture sits at the intersection of those themes.
New modality
A light-activated intracellular cytotoxic payload with a mechanism distinct from conventional systemic payloads.
Targeted intracellular delivery
The payload can be conjugated to partner-selected antibodies, peptides or ligands for intracellular delivery.
Biotherapeutic enabling technology
GenLumina is designed as an enabling payload layer rather than a technology tied to one proprietary target.
Oncology application
Internal breast and colorectal cancer programmes provide starting evidence while BI can select different tumor biology.
Partner targeting plus independent spatial activation.
BI-selected targeting
A Boehringer Ingelheim-selected antibody, peptide or ligand defines the relevant target biology.
GenLumina payload
The targeting molecule is conjugated with GenLumina's light-activated intracellular SnB payload.
Intracellular delivery
The combined construct is evaluated for uptake and localization within the intended tumor cells.
Spatial activation
Local light activates the payload within the treatment field, adding a second control layer to molecular targeting.
Enough evidence to ask the partner-specific question.
GenLumina's internal programmes establish the platform concept. The next value step is not another generic target: it is testing whether the platform performs with targeting biology selected by a pharmaceutical partner.
- Targeted and conjugated in-vitro proof-of-concept
- Activity in breast and colorectal cancer models
- Antibody- and peptide-based internal starting points
- Preclinical safety and biodistribution work
- Conjugation with a BI-selected antibody, peptide or ligand
- Construct stability and reproducibility
- Cellular uptake and intracellular localization
- Controlled activation, tumor-cell killing and selectivity
- Progression to in-vivo PoC if predefined criteria are met
BI does not need to adopt an existing GenLumina target.
GL-001 and GL-002 are internal evidence programmes. Their purpose is to demonstrate that the same controllable payload architecture can be evaluated across different targeting modalities. A BI programme can start with different targeting biology entirely.
Start with one focused scientific question.
Can a Boehringer Ingelheim-selected tumor-targeting molecule be combined with the GenLumina payload to create a differentiated conjugate with independent spatial activation?
Conjugation feasibility, construct quality, stability and reproducibility.
Cellular uptake, intracellular localization, controlled activation, tumor-cell killing and selectivity.
Progress to in-vivo PoC if jointly predefined technical and biological criteria are met.
Validate first. Create the option to license.
The initial objective is a focused proof-of-concept, not a broad platform licence or joint venture. The parties can define upfront how successful validation could create an option to progress toward programme-specific commercial rights.
BI targeting biology
Select one antibody, peptide or ligand relevant to a Boehringer Ingelheim oncology programme.
Partner-specific PoC
Evaluate the combination against jointly agreed technical and biological criteria.
Decide whether to advance
If the PoC is successful, BI can progress an agreed option toward broader development rights.
Programme-specific rights
Rights can then be negotiated for a defined programme, indication and geographic territory while GenLumina retains the underlying payload platform.
The intended model allows Boehringer Ingelheim to develop rights around a defined programme while GenLumina retains the core platform for other targets, indications and partners.
Which BI targeting molecule should we test first?
A first discussion can identify one antibody, peptide or ligand, define the feasibility package and agree which evidence should determine whether the programme advances.